annettchen
09-26-2014, 07:54 AM
Treatment with the combination of bevacizumab (Avastin) and chemotherapy improved progression-free survival (PFS) and overall survival (OS) in women with HER2-negative metastatic breast cancer, according to two phase III studies being presented at the 2014 ESMO Congress later this week.
http://www.onclive.com/conference-coverage/esmo-2014/Bevacizumab-Improves-Survival-in-Metastatic-Breast-Cancer
http://www.onclive.com/conference-coverage/esmo-2014/Bevacizumab-Improves-Survival-in-Metastatic-Breast-Cancer